Thiol-Based Redox Molecules: Potential Antidotes for Acrylamide Toxicity

Area of Science:

• Biochemistry and Molecular Biology
• Toxicology and Pharmacology
• Neuroscience

Background:

• Acrylamide (ACR) is a ubiquitous industrial chemical and food contaminant linked to oxidative stress and neurotoxicity.
• Oxidative stress induced by ACR involves the activation of mitogen-activated protein kinases (MAPKs), including ERK1/2, p38^MAPK, and JNKs.
• Identifying effective antidotes for ACR toxicity is crucial for mitigating its adverse health effects.

Purpose of the Study:

• To evaluate the efficacy of thiol-based molecules as potential antidotes against acrylamide (ACR) toxicity.
• To investigate the ability of these compounds to inhibit ACR-induced activation of extracellular-signal-regulated-kinases (ERK1/2), p38-mitogen-activated-protein-kinases (p38^MAPK), and c-Jun-N-terminal-kinases (JNKs).
• To explore the potential of these molecules in preventing ACR-triggered Parkinson's disease (PD)-like neurotoxic symptoms.

Main Methods:

• Development of a reproducible assay in PC12 cells to test N-acetylcysteine (NAC), AD4/NACA, and various thioredoxin-mimetic (TXM) peptides.
• Assessment of the compounds' efficacy in suppressing ACR-induced MAPK activation, both before and after ACR exposure.
• Dose-response analysis to determine the correlation between compound structure (number of cysteine residues) and inhibitory potency.

Main Results:

• All tested thiol-based compounds, including NAC, AD4/NACA, and TXM peptides, demonstrated significant efficacy in suppressing ACR-induced MAPK activation.
• Inhibitory potency was dose-dependent and directly correlated with the number of cysteine (Cys) residues in the molecules.
• SuperDopa (SD), a TXM peptide containing levodopa and two Cys residues, showed potential in mitigating PD-like symptoms by reducing oxidative stress and replenishing dopamine.

Conclusions:

• Thiol-based molecules, especially TXM peptides, are effective in counteracting ACR-induced MAPK activation and oxidative stress.
• The number of cysteine residues is a key factor in the potency of these antidotes.
• TXM peptides, including SD, hold promise as therapeutic agents for acute/chronic ACR exposure and for preventing ACR-induced Parkinsonism.